Other Health

Mesoblast says Ryoncil payer coverage extended to over 100 million Americans April 22, 2025

Allogeneic cell therapy company Mesoblast (ASX:MSB) has announced expanded US payer coverage for its Ryoncil (remestemcel-L), the first mesenchymal stromal cell therapy approved by the US FDA.

Anatara provides update following completion of analysis of Phase 2 GaRP-IBS clinical trial April 22, 2025

Anatara Lifesciences (ASX:ANR) has updated investors on an analysis following the completion of Stage 2 of its GaRP-IBS (Irritable Bowel Syndrome) trial.

Recce Phase 2 trial receives additional approval for treating diabetic patients with topical gel April 22, 2025

Recce Pharmaceuticals (ASX:RCE) has received Human Research Ethics Approval (HREC) to enrol up to 20 additional patients with Diabetic Foot Infections in its Phase 2 trial of R327G.

Race says patient enrolment opened at second site for RC220 solid tumour trial April 22, 2025

Race Oncology (ASX:RAC) has announced the activation of the second site for patient enrolment for its Phase 1 clinical trial of RC220 (bisantrene), combined with doxorubicin, in patients with advanced solid tumours.

Neurizon announces the appointment of chief financial officer April 22, 2025

Clinical-stage company Neurizon Therapeutics (ASX:NUZ) has announced the appointment of Dan O’Connell as chief financial officer.

Lilly records another win in weight loss in trial of oral GLP-1 agonist April 22, 2025

Another positive development for Lilly's weight-loss portfolio, with the company reporting positive results from its Phase 3 trial of a once-daily oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist.

Pharmac proposes three-monthly quantities for popular asthma inhalers April 22, 2025

New Zealand's Pharmac is proposing to increase the dispensed quantities for a type of asthma inhaler to provide for a three-month supply.

Australia increasingly isolated after Europe approves Alzheimer's therapy April 22, 2025

Australia's regulator looks increasingly isolated after the European Union approved Eisai and Biogen's monoclonal antibody LEQEMBI (lecanemab) for early Alzheimer's Disease.

FDA removes industry representatives from its advisory committees April 22, 2025

Patients and carers will replace industry employees on FDA advisory committees following a decision by Commissioner Dr Martin Makary that is less practically replicable in Australia.

'Arguing over the proverbial lifejacket whilst patients are in the water drowning. Shame' April 22, 2025

Rare Cancers Australia chief executive Christine Cockburn is understandably frustrated, using the term 'shame' to describe the recent dialogue between the Pharmaceutical Benefits Advisory Committee and industry.

A mixed bag for the industry in Trump executive order on medicine pricing April 17, 2025

The US biopharmaceutical industry will welcome the Trump administration's move to scrap the so-called 'pill penalty' introduced as part of the Biden administration's Inflation Reduction Act but will be less supportive of other proposed measures.

Telix says IPAX-Linz study shows promising efficacy for glioma therapy candidate April 16, 2025

Telix Pharmaceuticals (ASX:TLX) has announced that preliminary results from the Phase 2 IPAX-Linz study of TLX101 in recurrent high-grade glioma support the patient benefit seen in the IPAX-1 study.

Latest Video

Most Read

'Arguing over the proverbial lifejacket whilst patients are in the water drowning. Shame'

Australia increasingly isolated after Europe approves Alzheimer's therapy

Lilly records another win in weight loss in trial of oral GLP-1 agonist

FDA removes industry representatives from its advisory committees

Pharmac proposes three-monthly quantities for popular asthma inhalers

New Stories

Mesoblast says Ryoncil payer coverage extended to over 100 million Americans

Anatara provides update following completion of analysis of Phase 2 GaRP-IBS clinical trial

Recce Phase 2 trial receives additional approval for treating diabetic patients with topical gel

Race says patient enrolment opened at second site for RC220 solid tumour trial

Neurizon announces the appointment of chief financial officer

Australia increasingly isolated after Europe approves Alzheimer's therapy

Pharmac proposes three-monthly quantities for popular asthma inhalers

Sign In

Latest Video

Most Read

'Arguing over the proverbial lifejacket whilst patients are in the water drowning. Shame'

Australia increasingly isolated after Europe approves Alzheimer's therapy

Lilly records another win in weight loss in trial of oral GLP-1 agonist

FDA removes industry representatives from its advisory committees

Pharmac proposes three-monthly quantities for popular asthma inhalers

Follow Us

New Stories

Mesoblast says Ryoncil payer coverage extended to over 100 million Americans

Anatara provides update following completion of analysis of Phase 2 GaRP-IBS clinical trial

Recce Phase 2 trial receives additional approval for treating diabetic patients with topical gel

Race says patient enrolment opened at second site for RC220 solid tumour trial

Neurizon announces the appointment of chief financial officer

Australia increasingly isolated after Europe approves Alzheimer's therapy

Pharmac proposes three-monthly quantities for popular asthma inhalers